preclinical models
| 3 min read
Patient advocates warn that political momentum to reduce animal testing is outpacing the scientific validation of alternative methods.
Discover how multi-system proteomics and metabolic phenotyping reveal the tissue-level cellular mechanisms behind modern obesity treatments.
| 4 min read
As drug discovery adopts more human-relevant models and complex biologics, it’s increasingly important that reagents are more consistent, better characterized, and fit for purpose.
| 4 min read
As multiplexing platforms become more scalable and flexible, biomarkers are playing an increasingly central role in both preclinical and clinical decision-making.
| 6 min read
NAMs are increasingly used to de-risk preclinical development decisions, yet their broader impact on toxicology will depend on whether they are required or simply encouraged by regulators.
| 3 min read
Using an unbiased molecular screen, researchers found a new gene that could be targeted to treat fragile X syndrome.
| 6 min read
Despite growing regulatory acceptance, widespread adoption of NAMs depends on workflow integration, reproducibility, and perceived risk in industry decision-making.
Available on Demand
Learn how evidence-based enrichment strategies can better support laboratory animal welfare by promoting natural behaviors and reducing stress.
| 5 min read
Researchers identify a slow-cycling, therapy-tolerant state in breast cancer cells linked to Rac1 signaling and late metastatic relapse.
| 6 min read
The compound reduced opioid intake within hours in rats and was linked to changes in synaptic organization and gene expression in reward-related brain regions.
